Recombinant human factor IX: Replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B

被引:43
作者
Brinkhous, KM
Sigman, JL
Read, MS
Stewart, PF
McCarthy, KP
Timony, GA
Leppanen, SD
Rup, BJ
Keith, JC
Garzone, PD
Schaub, RG
机构
[1] UNIV N CAROLINA, CTR THROMBOSIS & HEMOSTASIS, CHAPEL HILL, NC 27599 USA
[2] GENET INST INC, ANDOVER, MA USA
关键词
D O I
10.1182/blood.V88.7.2603.bloodjournal8872603
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Recombinant human factor IX (rFIX) has been expressed in transduced cultured cell systems since 1985. Because there has been limited in vivo testing of rFIX in hemophilia B subjects, this study was undertaken using the severe hemophilia B canines of the Chapel Hill strain. Three groups of hemophilic dogs received either 50, 100, or 200 IU/kg of rFIX. As a control, a fourth group of hemophilic dogs received 50 IU/kg of a high purity. plasma-derived human FIX (pdFIX). The coagulant and hemostatic effects of rFIX and pdFIX were similar with all comparative dosing regimens. Based on activity data, the elimination half-life of rFIX was 18.9 +/- 2.3 hours and pdFIX was 17.9 +/- 2.1 hours. A prophylactic regimen administering rFIX daily resulted in a continuous therapeutic level of plasma FIX and was accompanied by a twofold increase in recovery levels by day 5, compared to that observed with administration of a single bolus. The mechanisms of the high to complete recovery of FIX with the prophylactic regimen could depend not only on the degree of saturation of the vascular endothelial binding sites but also on the altered dynamics of the balance of FIX distribution between the intravascular and extravascular compartments. The pharmacokinetic (PK) parameters for rFIX and pdFIX were similar. However, the relative PK values for V-1 and V-ss of both products on day 5 differed greatly from day 1 and may reflect the changing equilibrium of FIX between compartments with elevated levels of plasma FIX. Neutralizing antihuman FIX antibodies resulting from human FIX antigen being administered to FIX deficient dogs were observed beginning at 14 days. The antigenicity of rFIX and pdFIX appeared to be comparable. Despite the very different procedures used for production of rFIX and pdFIX products, in vivo testing in hemophilia B dogs showed the functional behavior of these products is similar; they are highly effective for replacement therapy and for prophylaxis. (C) 1996 by The American Society of Hematology.
引用
收藏
页码:2603 / 2610
页数:8
相关论文
共 64 条
[1]   EXPRESSION OF ACTIVE HUMAN CLOTTING FACTOR-IX FROM RECOMBINANT DNA CLONES IN MAMMALIAN-CELLS [J].
ANSON, DS ;
AUSTEN, DEG ;
BROWNLEE, GG .
NATURE, 1985, 315 (6021) :683-685
[2]  
ASTERMARK J, 1991, J BIOL CHEM, V266, P2438
[3]  
BARROW EM, 1960, J LAB CLIN MED, V55, P936
[4]  
BERNTORP E, 1993, THROMB HAEMOSTASIS, V70, P768
[5]  
BJORKMAN S, 1994, EUR J CLIN PHARMACOL, V46, P325
[6]  
BRINKHOUS K, 1994, BLOOD, V84, pA64
[7]   PURIFIED HUMAN FACTOR-VIII PROCOAGULANT PROTEIN - COMPARATIVE HEMOSTATIC RESPONSE AFTER INFUSIONS INTO HEMOPHILIC AND VONWILLEBRAND DISEASE DOGS [J].
BRINKHOUS, KM ;
SANDBERG, H ;
GARRIS, JB ;
MATTSSON, C ;
PALM, M ;
GRIGGS, T ;
READ, MS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (24) :8752-8756
[8]   GENE-TRANSFER IN THE HEMOPHILIAS - RETROSPECT AND PROSPECT [J].
BRINKHOUS, KM .
THROMBOSIS RESEARCH, 1992, 67 (03) :329-338
[9]   EXPRESSION OF ACTIVE HUMAN FACTOR-IX IN TRANSFECTED CELLS [J].
BUSBY, S ;
KUMAR, A ;
JOSEPH, M ;
HALFPAP, L ;
INSLEY, M ;
BERKNER, K ;
KURACHI, K ;
WOODBURY, R .
NATURE, 1985, 316 (6025) :271-273
[10]  
CHEUNG WF, 1992, J BIOL CHEM, V267, P20529